Treatment of Cutaneous Leishmaniasis (CL) according to WHO is depend on pentavalent antimonials as first-line treatment which requires multiple injections, painful, costly; as such not tolerated by most of the patients resulted in low compliance, justify to search for more effective and tolerable treatment for CL. In this study the efficacy of topical Nano liposomal form of Amphotericin B, twice a day for 28 days in combination with National standard treatment will be compared with National standard treatment for the treatment of CL caused by L. tropica. Inclusion criteria are parasitologically proven cases of CL based on positive smear and/or culture and PCR, age 12-60 years and exclusion criteria are pregnant or lactating women and duration of lesion more than 6 months. Each patient will be clinically checked and samples from the lesion will be taken to test for direct smear, culture and PCR. If the patient agrees to sign an informed consent will be included in the study. All the patients will be receiving Glucantime as National CL treatment, and double blind randomly will be treated with topical Nano liposomal Amphotericin B or placebo, twice a day for 28 days. The patients will be visited on day 1, 7, 14, 21, 28, 35, 42, 56, 90 and 180. The lesion(s) characteristics and size will be recorded at each visit and the data will double enter the computer and will be analyzed to compare the two group treatments. The clinical trial will carried out according to GCP (Good Clinical Practice) guide lines.